- Home
- SNAL vs CELU Comparison
SNAL vs CELU Comparison
Compare SNAL & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | CELU |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 34.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNAL | CELU |
|---|---|---|
| Price | $0.59 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 42.2K | 31.7K |
| Earning Date | 03-25-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,330,445.00 | $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $50.41 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $1.00 |
| 52 Week High | $2.84 | $4.35 |
Technical Indicators
Market Signals| Indicator | SNAL | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 44.78 |
| Support Level | $0.58 | $1.20 |
| Resistance Level | $0.69 | $1.31 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 4.84 | 41.75 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.